Trials / Recruiting
RecruitingNCT05802836
Dynamics of the Anti-factor VIII Antibody Signature During Treatment With Emicizumab
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 100 (estimated)
- Sponsor
- Christoph Königs · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The goal of this observational study is to learn about the changes of antibodies and inhibitors against the coagulation factor VIII in patients with severe hemophilia A receiving emicizumab therapy. No additional visits or procedures are planned. Patients in this study will continue to receive their routine care and analysis will be done from left over samples from routine visits.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | no interventions | no intervention, only 3 different patients groups |
Timeline
- Start date
- 2023-04-26
- Primary completion
- 2028-12-01
- Completion
- 2029-12-01
- First posted
- 2023-04-07
- Last updated
- 2023-07-10
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT05802836. Inclusion in this directory is not an endorsement.